Abstract
Ciprofloxacin is a new synthetic 4-quinolone with marked antibacterial activity against a wide spectrum of aerobic gram-negative bacteria (1). In view of its in vitro activity ciprofloxacin shows great potential as an antibiotic for oral treatment of infections caused by resistant gram-negative organisms (2). The lack of cross-resistance with other groups of agents such as beta-lactam antibiotics and aminoglycosides is advantageous particularly since no plasmid-mediated resistance has been found (3).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
King, A., Shannon, K., Phillips, I.: The in vitro activities of enoxacin and ofloxacin compared with that of ciprofloxacin. Journal of Antimicrobial Chemotherapy 1985, 15: 551–558.
Palton, W. N., Smith, G. N., Leyland, M. J., Geddes, A. M.: Multiply resistant Salmonella typhimurium septicaemia in an immunocompromised patient successfully treated with ciprofloxacin. Journal of Antimicrobial Chemotherapy 1985, 16: 667–669.
Smith, J. T.: Mutational resistance to 4-quinolone antibacterial agents. European Journal of Clinical Microbiology 1984, 3: 347–350.
Author information
Authors and Affiliations
Editor information
Rights and permissions
Copyright information
© 1986 Springer Fachmedien Wiesbaden
About this chapter
Cite this chapter
Mehtar, S., Drabu, Y., Blakemore, P. (1986). Ciprofloxacin in the Treatment of Infections Caused by Gentamicin-Resistant Gram-Negative Bacteria. In: Neu, H.C., Reeves, D.S. (eds) Ciprofloxacin. Current Topics in Infectious Diseases and Clinical Microbiology, vol 1. Vieweg+Teubner Verlag, Wiesbaden. https://doi.org/10.1007/978-3-663-01930-5_35
Download citation
DOI: https://doi.org/10.1007/978-3-663-01930-5_35
Publisher Name: Vieweg+Teubner Verlag, Wiesbaden
Print ISBN: 978-3-663-01931-2
Online ISBN: 978-3-663-01930-5
eBook Packages: Springer Book Archive